Effects of Omega-3 Supplementation on Motor Performance and Bone Turnover Markers in Women: A Pilot Study (OMEGA3-FEMALE)

November 9, 2026 updated by: Aleksandra Sarachman, Wroclaw University of Health and Sport Sciences

Effects of Omega-3 Fatty Acid Supplementation on Selected Measures of Motor Performance and Bone Turnover Markers in Female Soccer Players and Women With Low Physical Activity: A Randomized, Double-Blind, Placebo-Controlled - Pilot Study

The aim of this pilot study is to assess the effects of 10 weeks of omega-3 fatty acid supplementation on selected motor performance parameters, bone turnover markers, regulators of bone remodeling, and bone mineral density in female soccer players and women with low levels of physical activity. Changes in the erythrocyte omega-3 fatty acid profile, including EPA and DHA levels and the Omega-3 Index, will also be assessed, along with potential differences in response to supplementation between the two populations.

This will be an interventional, randomized, double-blind, placebo-controlled study. A total of 40 women aged 18-35 years will be enrolled: 20 female soccer players and 20 women with low levels of physical activity. Within each population, participants will be randomly allocated in a 1:1 ratio to the omega-3 supplementation or placebo group, yielding four parallel study groups. Over 10 weeks, participants assigned to omega-3 will take three capsules daily providing 1,677 mg of EPA and 687 mg of DHA. Participants assigned to placebo will take three capsules daily providing a total of 3,000 mg of MCT oil.

Assessments will be performed at three time points: T0 (baseline, before the start of supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). Assessments will include handgrip strength, back muscle strength, lower-limb power assessed by vertical jump testing, bone turnover markers and regulators of bone remodeling, body composition and bone mineral density measured by DXA, the erythrocyte fatty acid profile, selected hormonal parameters, and dietary intake.

The effects of supplementation will be evaluated by assessing changes in the measured parameters at weeks 5 and 10 relative to baseline (T0). The magnitude of these changes will also be compared between the omega-3 and placebo groups, taking participants' level of physical activity into account.

Study Overview

Detailed Description

Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are involved in numerous physiological processes, including regulation of inflammatory responses and the functioning of skeletal muscle and bone tissue. However, scientific evidence regarding the effects of omega-3 supplementation on physical performance and bone metabolism remains inconclusive, particularly among physically active women. This pilot study will assess responses to a controlled supplementation intervention in female soccer players and women with low levels of physical activity.

The study is interventional, randomized, placebo-controlled, and double-blind. It will include 40 women aged 18-35 years: 20 female soccer players and 20 women with low levels of physical activity. Randomization will be conducted separately within each population in a 1:1 ratio, resulting in four groups: female soccer players receiving omega-3, female soccer players receiving placebo, women with low levels of physical activity receiving omega-3, and women with low levels of physical activity receiving placebo. Treatment allocation will remain concealed from participants, outcome assessors, and data analysts until study completion and database lock.

For 10 weeks, participants in the active supplementation groups will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily, providing 3,000 mg of concentrated fish oil, including 1,677 mg of EPA and 687 mg of DHA. Participants in the placebo groups will take three NOW Foods MCT Oil 1000 mg capsules daily, providing 3,000 mg of MCT oil. Supplement adherence and any adverse events will be monitored using participant records, contact with the research team, and counts of unused capsules.

Assessments will be conducted at three time points: T0 (baseline, before supplementation), T1 (after 5 weeks of supplementation), and T2 (after 10 weeks of supplementation). The T0 assessment will establish baseline values for the measured parameters, providing a reference for evaluating changes during the intervention. At each time point, motor performance will be assessed using handgrip strength, back muscle strength, and vertical jump tests. Body composition and bone mineral density will be assessed by dual-energy X-ray absorptiometry (DXA). Blood measurements will include the erythrocyte fatty acid profile and Omega-3 Index, estradiol and progesterone, and bone metabolism markers P1NP, CTX, OPG, RANKL, SOST, and DKK-1. Data on health status, menstrual cycle, hormonal contraception, physical activity, dietary intake, and anthropometry will also be collected.

The primary scientific aim is to assess the effects of omega-3 fatty acid supplementation compared with placebo on selected motor performance parameters, markers of bone turnover and remodeling, and bone mineral density. Intervention effects will be evaluated by comparing values at T1 and T2 with baseline values at T0, including comparisons between the omega-3 and placebo groups. Supplementary analyses will assess changes in EPA and DHA levels and potential differences in response between female soccer players and women with low levels of physical activity.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Poland, 51-612
        • Recruiting
        • Wroclaw University of Health and Sport Sciences
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Female soccer players:

  • Female sex, age 18-35 years.
  • Regular sports training for more than 10 hours per week.
  • Active participation in league competitions.
  • No medical contraindications to participation.
  • No injury resulting in a training interruption longer than 2 weeks during the 3 months before the study.
  • Written informed consent to participate, undergo blood collection, and have laboratory tests performed.

Women with low levels of physical activity:

  • Female sex, age 18-35 years.
  • Physical activity below 150 minutes per week.
  • Body mass index (BMI) between 18.5 and 24.9 kg/m².
  • No medical contraindications to participation.
  • Written informed consent to participate, undergo blood collection, and have laboratory tests performed.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Use of supplements containing omega-3 fatty acids within the 3 months before the study.
  • Allergy or hypersensitivity to fish, fish oil, gelatin, or other ingredients of the active supplement or placebo.
  • Diseases or use of medications that may substantially affect lipid metabolism, muscle function, or bone metabolism.
  • Neurological disorders.
  • Bleeding disorders or treatment considered by a physician to increase the risks associated with supplementation or blood sampling.
  • Injury or symptoms that prevent safe performance of motor tests.
  • Other contraindications identified during medical screening.
  • Failure to provide written informed consent to participate, undergo blood collection, and have the planned analyses performed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1 - Female Soccer Players: Omega-3

Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA.

Placebo Comparator: Arm 2 - Female Soccer Players: Placebo

Female soccer players actively participating in league competitions and training for more than 10 hours per week will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA.

Experimental: Arm 3 - Women With Low Levels of Physical Activity: Omega-3

Women with low levels of physical activity (less than 150 minutes per week) will take three NAMEDSPORT Omega 3 Double Plus ++ capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks. The daily dose will provide 3,000 mg of concentrated fish oil containing 2,457 mg of omega-3 fatty acids, including 1,677 mg of EPA and 687 mg of DHA.

Placebo Comparator: Arm 4 - Women With Low Levels of Physical Activity: Placebo

Women with low levels of physical activity (less than 150 minutes per week) will take three NOW Foods MCT Oil 1000 mg capsules daily for 10 weeks.

Participants will take three softgel capsules daily for 10 weeks, providing 3,000 mg of MCT oil per day. The placebo contains neither EPA nor DHA.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Handgrip Strength
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Handgrip strength will be assessed using a T.K.K. 5001 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Back Muscle Strength
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Back muscle strength will be measured using a T.K.K. 5402 dynamometer (Takei Scientific Instruments) at T0, T1, and T2. Changes after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Vertical Jump Performance
Time Frame: : T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Lower-limb power will be assessed using vertical jump testing with the OptoJump system (Microgate) at T0, T1, and T2. Changes in vertical jump results after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum P1NP Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Serum concentrations of the N-terminal propeptide of type I procollagen (P1NP), a marker of bone formation, will be determined by ELISA at T0, T1, and T2. Changes in P1NP concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum CTX Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Serum concentrations of the C-terminal telopeptide of type I collagen (CTX), a marker of bone resorption, will be measured at T0, T1, and T2. Changes in CTX concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Bone Mineral Density
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Whole-body bone mineral density (BMD) will be assessed by DXA using a Lunar iDXA scanner (GE HealthCare) at T0, T1, and T2. Changes in BMD after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Serum Osteoprotegerin Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Osteoprotegerin (OPG), a regulator of bone remodeling, will be measured in serum using ELISA at T0, T1, and T2. Changes in OPG concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum RANKL Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Receptor activator of nuclear factor kappa-B ligand (RANKL) will be measured in serum using ELISA at T0, T1, and T2. Changes in RANKL concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum Sclerostin Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Sclerostin (SOST) will be measured in serum using ELISA at T0, T1, and T2. Changes in SOST concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Serum DKK-1 Concentration
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Dickkopf-1 (DKK-1) protein will be measured in serum using ELISA at T0, T1, and T2. Changes in DKK-1 concentrations after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Erythrocyte EPA Content
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The proportion of eicosapentaenoic acid (EPA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in EPA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Erythrocyte DHA Content
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The proportion of docosahexaenoic acid (DHA) in the erythrocyte fatty acid profile will be determined by gas chromatography with flame ionization detection (GC-FID) at T0, T1, and T2. Changes in DHA content after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in Omega-3 Index
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The Omega-3 Index will be calculated from the combined proportion of EPA and DHA in the erythrocyte fatty acid profile at T0, T1, and T2. Changes in the Omega-3 Index after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)
Change in the Erythrocyte Omega-6 to Omega-3 Ratio
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

The omega-6 to omega-3 fatty acid ratio will be derived from the erythrocyte fatty acid profile measured by GC-FID at T0, T1, and T2. Changes in the omega-6 to omega-3 ratio after 5 and 10 weeks of supplementation relative to baseline will be analyzed, and these changes will be compared between the omega-3 and placebo groups.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Dietary Intake
Time Frame: T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Dietary intake will be assessed using a 72-item food frequency questionnaire and a 7-day food diary, including the intake of omega-3 fatty acids. Assessments will be conducted at T0, T1, and T2. Changes in dietary intake and omega-3 fatty acid consumption after 5 and 10 weeks of supplementation relative to baseline will be analyzed.

T0 (baseline, before supplementation), T1 (week 5), and T2 (week 10)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Anna Książek, PhD, DSc, Department of Biological Principles of Physical Activity Wroclaw University of Health and Sport Sciences, Poland 35 Paderewskiego Avenue, 51-612 Wrocław,

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 27, 2026

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared with external researchers or deposited in public repositories, even after removal of direct identifiers. Access to the data will be restricted to authorized members of the research team. Study results will be published only in aggregate form, without disclosing participants' identities.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe